Prescribing preferences for hormone sensitive (HR plus ) metastatic breast cancer (mBC) in the CDK 4/6 inhibitor (CDK 4/6i) era.

Feinberg, BA; Wojtynek, J; Dokubo, I; Jeune-Smith, Y; Kish, J; Gajra, A

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索